ICON (NasdaqGS:ICLR) reported its third quarter 2025 results, largely meeting expectations and easing some market concerns. The company not only raised its full-year revenue outlook but also pushed forward on share buybacks and key technological investments.

Despite steady business wins and a well-received clinical partnership, ICON’s shares have been on a rocky path lately, with a 1-day share price return of -6.6% following its earnings update and a year-to-date drop of nearly 22%. While short-term price swings have raised eyebrows, the longer-term story reflects a total shareholder return of -27% over the past year. Even with management’s push for buybacks and raised revenue guidance, momentum has been slow to rebuild.

If ICON’s changing outlook has you rethinking where opportunities might be emerging, now is the perfect moment to broaden your search and discover fast growing stocks with high insider ownership.

With shares now trading at a sizable discount to analyst and intrinsic valuations, the real question is whether ICON offers a window for long-term gains or if the market has already factored in every catalyst on the horizon.

Most Popular Narrative: 20.6% Undervalued

ICON's most widely followed narrative sets a fair value that is over 20% higher than the recent share price, highlighting the disconnect between fundamental earnings potential and short-term sentiment. This underscores expectations for a significant price rebound if projected growth is realized.

Analysts are assuming ICON's revenue will grow by 2.9% annually over the next 3 years. Analysts assume that profit margins will increase from 9.8% today to 11.7% in 3 years time.

Want to discover the bold financial targets analysts are using to support this valuation gap? There is a striking set of projections around future earnings, revenue momentum, and margin improvement hiding behind these numbers. If you want to see how the narrative justifies such optimism, you’ll want to dig into the full assumptions behind this price target.

Result: Fair Value of $208.93 (UNDERVALUED)

However, lingering concerns around elevated clinical trial cancellations and persistent margin pressures could alter this upbeat outlook if these issues persist longer than expected.

Build Your Own ICON Narrative

If you want to challenge the consensus or see where your own analysis leads, now’s your chance to build a unique investment case in minutes. Do it your way.

A great starting point for your ICON research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Smart investors always keep their radar open for fresh opportunities. Don’t let the next big winner slip by. Put the Simply Wall Street Screener to work for you right now.

• Uncover tomorrow’s market leaders by reviewing these 3583 penny stocks with strong financials that are driving massive growth with innovative business models and untapped potential.
• Boost your income by targeting reliable returns. Choose from these 21 dividend stocks with yields > 3% that offer solid yields and robust track records.
• Seize the future of artificial intelligence by selecting from these 26 AI penny stocks poised to disrupt industries with smarter, faster technology.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.